scholarly journals Presentation and Management of Arterial Thromboembolisms During Active Inflammatory Bowel Disease: Case Series and Literature Review

2020 ◽  
Vol 72 (2) ◽  
pp. 748
Author(s):  
M. Pezold ◽  
M. Pergamo ◽  
C. Rockman ◽  
J. Lugo
Keyword(s):  
Inflammatory Bowel Disease ◽  
Literature Review ◽  
Bowel Disease ◽  
Case Series ◽  
Active Inflammatory Bowel Disease ◽  
Disease Case ◽  
Inflammatory Bowel

Autoimmune pancreatitis and inflammatory bowel disease: Case series and review of the literature

2016 ◽  
Vol 48 (8) ◽  
pp. 893-898 ◽  
Author(s):  
Lídia Roque Ramos ◽  
Christopher J. DiMaio ◽  
David B. Sachar ◽  
Ashish Atreja ◽  
Jean-Frédéric Colombel ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Autoimmune Pancreatitis ◽  
Bowel Disease ◽  
Case Series ◽  
Review Of The Literature ◽  
Disease Case ◽  
Inflammatory Bowel

Antitumor Necrosis Factor-α Therapy Associated with Inflammatory Bowel Disease: Three Cases and a Systematic Literature Review

2017 ◽  
Vol 44 (7) ◽  
pp. 1088-1095 ◽  
Author(s):  
Amir Bieber ◽  
Abdallah Fawaz ◽  
Irina Novofastovski ◽  
Reuven Mader
Keyword(s):  
Inflammatory Bowel Disease ◽  
Literature Review ◽  
Bowel Disease ◽  
Gastrointestinal Symptoms ◽  
Case Series ◽  
Patient Specific ◽  
Tnf Α ◽  
Inflammatory Bowel ◽  
Factor Α ◽  
Necrosis Factor

Objective.Antitumor necrosis factor-α (anti-TNF-α) therapy is the most prescribed biologic agent therapy in rheumatology and gastroenterology. However, a number of serious side effects have been reported with these drugs. Only a handful of cases of new-onset inflammatory bowel disease (IBD), mostly in children diagnosed with juvenile idiopathic arthritis (JIA), have been reported during anti-TNF-α therapy. We present 3 cases of adult IBD following anti-TNF-α therapy and a literature review on this topic.Methods.We searched PubMed MESH for all relevant terms, papers were reviewed, and patient-specific data were extracted. Relevant clinical data were calculated and presented.Results.The PubMed search resulted in 137 articles, of which 11 articles and 4 cited publications were included in our analysis. We found 53 cases of IBD after anti-TNF-α therapy reported in the literature; most of them were case series collected retrospectively from national databases or studies. Almost all the patients developed IBD after the introduction of etanercept (ETN); 2 patients with rheumatoid arthritis were also included. The average age at IBD onset was 17.3 years and the average time from ETN introduction to IBD onset was 27 months (± 24). Gastrointestinal symptoms have been reported as improving or subsiding in most of the patients after discontinuing ETN.Conclusion.Although this manifestation is not common, it should be taken into consideration as an adverse effect of ETN. Rheumatologists, and in particular rheumatologists treating adult patients, should be aware of this possible complication. Further investigation about the pathogenic process underlying this phenomenon is warranted.

Safety of Combination Biologic and Antirejection Therapy Post–Liver Transplantation in Patients With Inflammatory Bowel Disease

2019 ◽  
Author(s):  
Saleh Al Draiweesh ◽  
Christopher Ma ◽  
Maan Alkhattabi ◽  
Cassandra McDonald ◽  
Tran M Nguyen ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Clostridium Difficile ◽  
Literature Review ◽  
Liver Transplant ◽  
Bowel Disease ◽  
Case Series ◽  
Tnf Antagonists ◽  
Increased Risk ◽  
Tertiary Center ◽  
Inflammatory Bowel

Abstract Background Patients with inflammatory bowel disease (IBD) post–liver transplant (LT) may have bowel inflammation requiring biologic therapy. We aimed to evaluate the safety of combination biologic and antirejection therapy in IBD patients after LT from a tertiary center case series and an updated literature review. Methods Inflammatory bowel disease patients undergoing LT between 1985 and 2018 and requiring combination biologic and antirejection therapy post-LT were identified from the London Health Sciences Transplant Registry (Ontario, Canada). Safety outcomes were extracted by medical chart review. For an updated literature review, EMBASE, Medline, and CENTRAL were searched to identify studies evaluating the safety of combination biologic and antirejection therapy in IBD patients. Results In the case series, 19 patients were identified. Most underwent LT for primary sclerosing cholangitis (PSC; 14/19, 74%) treated with anti-integrins (8/19, 42%) or tumor necrosis factor α (TNF) antagonists (6/19, 32%). Infections occurred in 11/19 (58%) patients, most commonly Clostridium difficile (4/19, 21%). Two patients required colectomy, and 1 patient required re-transplantation. In the literature review, 13 case series and 8 case reports reporting outcomes for 122 IBD patients treated with biologic and antirejection therapy post-LT were included. PSC was the indication for LT in 97/122 (80%) patients, and 91/122 (75%) patients were treated with TNF antagonists. Infections occurred in 32/122 (26%) patients, primarily Clostridium difficile (7/122, 6%). Conclusions Inflammatory bowel disease patients receiving combination biologic and antirejection therapy post-LT appeared to be at increased risk of Clostridium difficile. Compared with the general liver transplant population in the published literature, there was no increased risk of serious infection.

Sign in / Sign up

Export Citation Format

Share Document